Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis

Rheumatology (Oxford). 2021 Feb 20;keab175. doi: 10.1093/rheumatology/keab175. Online ahead of print.
No abstract available